Skip to main content

Table 1 Characteristics of the study patients before and after propensity score matching

From: Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction

Variable

Before matching

After matching

Statin (n = 611)

Non-statin (n = 1370)

P value

Statin (n = 441)

Non-statin (n = 441)

P value

Age (year)

64.6 ± 10.2

67.5 ± 10.1

<.001

65.8 ± 10.2

65.6 ± 10.1

.844

Age group (years)

  

<.001

  

.933

 21–60

210 (34.4)

324 (23.6)

 

131 (29.7)

136 (30.8)

 

 61–80

365 (59.7)

891 (65.0)

 

276 (62.6)

271 (61.5)

 

 > 80

36 (5.9)

155 (11.3)

 

34 (7.7)

34 (7.7)

 

Gender

  

.038

  

.636

 Male

323 (52.9)

793 (57.9)

 

236 (53.5)

243 (55.1)

 

 Female

288 (47.1)

577 (42.1)

 

205 (46.5)

198 (44.9)

 

Dialysis

  

.033

  

1.000

 Hemodialysis

558 (91.3)

1287 (93.9)

 

402 (91.2)

402 (91.2)

 

 Peritoneal dialysis

53 (8.7)

83 (6.1)

 

39 (8.8)

39 (8.8)

 

Dialysis duration (year)

3.1 ± 2.9

3.1 ± 3.1

.949

3.3 ± 3.0

3.3 ± 3.3

.860

Diabetes mellitus duration (year)

11.3 ± 3.4

10.1 ± 3.8

<.001

11.2 ± 3.3

11.3 ± 3.4

.563

Comorbidity

 Hypertension

512 (83.8)

1045 (76.3)

<.001

367 (83.2)

363 (82.3)

.721

 Dyslipidemia

428 (70.0)

412 (30.1)

<.001

259 (58.7)

254 (57.6)

.733

 Heart failure

347 (56.8)

640 (46.7)

<.001

231 (52.4)

230 (52.2)

.946

 Old myocardial infarction

209 (34.2)

505 (36.9)

.256

156 (35.4)

141 (32.0)

.285

 Atrial fibrillation

49 (8.0)

113 (8.2)

.864

35 (7.9)

33 (7.5)

.801

 Peripheral arterial disease

99 (16.2)

228 (16.6)

.808

69 (15.6)

70 (15.9)

.926

 Chronic obstructive pulmonary disease

42 (6.9)

110 (8.0)

.372

30 (6.8)

29 (6.6)

.893

 Malignancy

45 (7.4)

107 (7.8)

.731

33 (7.5)

34 (7.7)

.899

 Cirrhosis

6 (1.0)

46 (3.4)

.002

6 (1.4)

6 (1.4)

1.000

 Gout

43 (7.0)

90 (6.6)

.700

28 (6.3)

33 (7.5)

.507

Previous PCI

201 (32.9)

385 (28.1)

.031

143 (32.4)

136 (30.8)

.612

Previous CABG

49 (8.0)

97 (7.1)

.460

33 (7.5)

32 (7.3)

.897

Old ischemic stroke

172 (28.2)

420 (30.7)

.260

124 (28.1)

130 (29.5)

.655

Old hemorrhage stroke

16 (2.6)

33 (2.4)

.781

12 (2.7)

10 (2.3)

.666

History of bleeding (major bleeding)

308 (50.4)

693 (50.6)

.943

227 (51.5)

223 (50.6)

.788

Medication

 Aspirin

429 (70.2)

648 (47.3)

<.001

287 (65.1)

291 (66.0)

.777

 Clopidogrel

494 (80.9)

670 (48.9)

<.001

338 (76.6)

331 (75.1)

.582

 Warfarin

12 (2.0)

15 (1.1)

.123

11 (2.5)

9 (2.0)

.651

 ACEI/ARB

343 (56.1)

481 (35.1)

<.001

220 (49.9)

226 (51.2)

.686

 β-blocker

370 (60.6)

487 (35.5)

<.001

239 (54.2)

225 (51.0)

.345

 Sulfonylurea

122 (20.0)

189 (13.8)

<.001

91 (20.6)

86 (19.5)

.674

 Thiazolidinediones

13 (2.1)

38 (2.8)

.402

12 (2.7)

11 (2.5)

.833

 Insulin

276 (45.2)

472 (34.5)

<.001

185 (42.0)

177 (40.1)

.584

  1. ACEi/ARB angiotensin-converting-enzyme inhibitor/angiotensin receptor blockers, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention